PASylation® is an innovative technology that extends the plasma half-life of biopharmaceuticals. In collaboration with XL-protein GmbH, a privately owned German biotech company, WACKER offers the production of PASylated biopharmaceuticals based on its proprietary ESETEC® E. coli secretion technology. Using this approach, for example, PASylated Fabs with yields > 3 g / L are possible.

Visit to learn more about PASylation®.